SEARCH

SEARCH BY CITATION

References

  • 1
    Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999; 103: 697705.
  • 2
    Kawada H, Fujita J, Kinjo K, Matsuzaki Y, Tsuma M, Miyatake H, et al. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 2004; 104: 35817.
  • 3
    Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002; 105: 938.
  • 4
    Uchiyama T, Engelman RM, Maulik N, Das DK. Role of Akt signaling in mitochondrial survival pathway triggered by hypoxic preconditioning. Circulation 2004; 109: 30429.
  • 5
    Xie XJ, Wang JA, Cao J, Zhang X. Differentiation of bone marrow mesenchymal stem cells induced by myocardial medium under hypoxic conditions. Acta Pharmacol Sin 2006; 27: 11538.
  • 6
    Zhu W, Chen J, Cong X, Hu S, Chen X. Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells. Stem Cells 2006; 24: 41625.
  • 7
    Geng YJ. Molecular mechanisms for cardiovascular stem cell apoptosis and growth in the hearts with atherosclerotic coronary disease and ischemic heart failure. Ann N Y Acad Sci 2003; 1010: 68797.
  • 8
    Suzuki K, Smolenski RT, Jayakumar J, Murtuza B, Brand NJ, Yacoub MH. Heat shock treatment enhances graft cell survival in skeletal myoblast transplantation to the heart. Circulation 2000; 102: 21621.
  • 9
    Tang YL, Tang Y, Zhang KC, Qian K, Shen L, Phillips MI. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol 2005; 46: 133950.
  • 10
    Song H, Kwon K, Lim S, Kang SM, Ko YG, Xu ZZ, Chung JH, et al. Transfection of mesenchymal stem cells with the FGF-2 gene improves their survival under hypoxic conditions. Mol Cells 2005; 19: 4027.
  • 11
    Noiseux N, Gnecchi M, Lopez-Ilasaca M, Zhang L, Solomon SD, Deb A, et al. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther 2006; 14: 84050.
  • 12
    Sartore S, Lenzi M, Angelini A, Chiavegato A, Gasparotto L, Coppi P, et al. Amniotic mesenchymal cells autotransplanted in a porcine model of cardiac ischemia do not differentiate to cardiogenic phenotypes. Eur J Cardiothorac Surg 2005; 28: 67784.
  • 13
    Dispersyn GD, Borgers M. Apoptosis in the heart: about programmed cell death and survival. News Physiol Sci 2001; 16: 417.
  • 14
    Zhang W, Liu HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 2002; 12: 918.
  • 15
    Lawlor MA, Alessi DR. PKB/Akt a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 2001; 114: 290310.
  • 16
    Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE, et al. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem 2000; 275: 107616.
  • 17
    Huang SJ, Cidlowski JA. Phosphorylation status modulates Bcl-2 function during glucocorticoid-induced apoptosis in T lymphocytes. FASEB J 2002; 16: 82532.
  • 18
    Gnecchi M, He HM, Liang OD, Melo LG, Morello F, Mu H, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005; 11: 3678.
  • 19
    Neubauer JA. Physiological and pathophysiological responses to intermittent hypoxia. J Appl Physiol 2001; 90:15939.
  • 20
    Semenza GL. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002; 64: 9938.
  • 21
    Gouill SL, Podar K, Amiot M, Hideshima T, Chauhan D, Ishitsuka K, et al. VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood 2004; 104: 288692.
  • 22
    Martinive P, Defresne F, Bouzin C, Saliez J, Lair F, Gregoire V, et al. Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res 2006; 15: 1173644.